NASDAQ · Financial Statements

Mirum Pharmaceuticals, Inc. (MIRM) Financial Statements

$80.39 NASDAQ: MIRM Market Cap $5.22B

Mirum Pharmaceuticals, Inc. most recently reported annual revenue of $521.0M, a net loss of $23.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Mirum Pharmaceuticals, Inc.: net profit was positive in 0 of 8 reported years; operating margin moved from -906.1% to -4.3%, a shift of +901.9 percentage points; the most recent year shows a net loss of $23.0M.

Income Statement — 8 Years (USD millions)

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$19.0M	$77.0M	$186.0M	$337.0M	$521.0M
Operating Expenses	$3.0M	$55.0M	$104.0M	$193.0M	$208.0M	$296.0M	$424.0M	$543.0M
Operating Profit	$-3.0M	$-55.0M	$-104.0M	$-173.0M	$-131.0M	$-109.0M	$-88.0M	$-22.0M
Operating Margin	0.0%	0.0%	0.0%	-906.1%	-170.3%	-58.6%	-26.0%	-4.3%
Other Income	$-14.0M	$2.0M	$1.0M	$89.0M	$-11.0M	$-53.0M	$1.0M	$1.0M
Interest	$0	$0	$0	$18.0M	$16.0M	$15.0M	$14.0M	$14.0M
Depreciation	$4.0M	$0	$1.0M	$1.0M	$3.0M	$11.0M	$24.0M	$24.0M
Profit Before Tax	$-17.0M	$-53.0M	$-103.0M	$-84.0M	$-142.0M	$-162.0M	$-87.0M	$-21.0M
Tax	$0	$-40,000	$-10,000	$-40,000	$4.5M	$-610,000	$-1.2M	$-9.0M
Net Profit	$-17.0M	$-53.0M	$-103.0M	$-84.0M	$-136.0M	$-163.0M	$-88.0M	$-23.0M
EPS	$-0.75	$-2.29	$-4.09	$-2.77	$-4.02	$-4.00	$-1.85	$-0.47
Dividend Payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

Metric	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
Revenue	$48.0M	$70.0M	$69.0M	$78.0M	$90.0M	$99.0M	$112.0M	$128.0M	$133.0M	$149.0M	$160.0M	$176.0M
Operating Expenses	$73.0M	$102.0M	$96.0M	$102.0M	$103.0M	$124.0M	$127.0M	$133.0M	$130.0M	$153.0M	$223.0M	$219.0M
Operating Profit	$-25.0M	$-33.0M	$-26.0M	$-24.0M	$-13.0M	$-24.0M	$-15.0M	$-5.0M	$3.0M	$-5.0M	$-63.0M	$-43.0M
Operating Margin	-52.7%	-46.9%	-38.2%	-31.1%	-14.0%	-24.4%	-13.6%	-3.9%	2.0%	-3.1%	-39.5%	-24.1%
Interest	$4.0M	$4.0M	$4.0M	$4.0M	$4.0M	$4.0M	$4.0M	$4.0M	$4.0M	$4.0M	$4.0M	$3.0M
Profit Before Tax	$-23.0M	$-35.0M	$-25.0M	$-24.0M	$-14.0M	$-24.0M	$-14.0M	$-5.0M	$3.0M	$-5.0M	$-790.0M	$-66.0M
Tax	$-1.1M	$-630,000	$-2.5M	$-2.6M	$-2.5M	$2.4M	$-7.5M	$-7.4M	$-9.9M	$-15.4M	$-60,000	$-2.6M
Net Profit	$-24.0M	$-36.0M	$-25.0M	$-25.0M	$-14.0M	$-24.0M	$-15.0M	$-6.0M	$3.0M	$-6.0M	$-790.0M	$-67.0M
EPS	$-0.57	$-0.71	$-0.54	$-0.52	$-0.30	$-0.49	$-0.30	$-0.12	$0.05	$-0.12	$-13.43	$-1.06

Over the 8 years reported for Mirum Pharmaceuticals, Inc., cash stood at $297.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.67 times.

Balance Sheet — 8 Years (USD millions)

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	$52.0M	$147.0M	$241.0M	$295.0M	$353.0M	$647.0M	$671.0M	$843.0M
Current Assets	$52.0M	$119.0M	$236.0M	$167.0M	$190.0M	$388.0M	$393.0M	$550.0M
Cash	$52.0M	$12.0M	$142.0M	$31.0M	$28.0M	$286.0M	$223.0M	$297.0M
Inventory	$0	$0	$0	$2.0M	$6.0M	$22.0M	$22.0M	$25.0M
Receivables	$0	$0	$0	$4.0M	$24.0M	$68.0M	$78.0M	$123.0M
Fixed Assets	$0	$4.0M	$3.0M	$3.0M	$2.0M	$2.0M	$10.0M	$11.0M
Capital Work in Progress	$0	$0	$0	$0	$0	$0	$0	$0
Investments	$0	$128.0M	$90.0M	$130.0M	$124.0M	$0	$70.0M	$95.0M
Other Assets	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$62.0M	$16.0M	$69.0M	$174.0M	$211.0M	$398.0M	$445.0M	$528.0M
Current Liabilities	$2.0M	$13.0M	$18.0M	$43.0M	$65.0M	$87.0M	$127.0M	$206.0M
Borrowings	$0	$4.0M	$3.0M	$3.0M	$2.0M	$308.0M	$318.0M	$319.0M
Other Liabilities	$62.0M	$13.0M	$66.0M	$172.0M	$209.0M	$90.0M	$127.0M	$209.0M
Equity	$7.0M	$0	$0	$0	$0	$0	$0	$0
Reserves	$-10.0M	$130.0M	$172.0M	$120.0M	$142.0M	$249.0M	$226.0M	$315.0M

For Mirum Pharmaceuticals, Inc., operating cash flow was positive in 2 of 8 reported years; free cash flow in the latest year was $55.0M; free cash flow was positive in 2 of 8 years.

Cash Flow Statement — 8 Years (USD millions)

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Operating Cash Flow	$0	$-39.0M	$-89.0M	$-133.0M	$-120.0M	$-71.0M	$10.0M	$56.0M
Investing Cash Flow	$-26.0M	$-128.0M	$38.0M	$30.0M	$7.0M	$-127.0M	$-91.0M	$-25.0M
Financing Cash Flow	$0	$0	$49.0M	$67.0M	$2.0M	$-185.0M	$0	$0
Net Cash Flow	$52.0M	$-40.0M	$130.0M	$-11.0M	$-3.0M	$158.0M	$-63.0M	$75.0M
Free Cash Flow	$-8.0M	$-40.0M	$-89.0M	$-152.0M	$-120.0M	$-91.0M	$9.0M	$55.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-7.25
FCF Yield	-8.80%
Quick Ratio	2.74
Interest Coverage	-8.01
Return 1Y	36.02%
Return 3Y	265.31%
Return 5Y	454.61%

Mirum Pharmaceuticals, Inc. (MIRM) financials — frequently asked questions

What is Mirum Pharmaceuticals, Inc.'s annual revenue?

Mirum Pharmaceuticals, Inc. (MIRM) reported annual revenue of $521.0M in its most recent fiscal year.

What is Mirum Pharmaceuticals, Inc.'s net profit?

Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $23.0M in its most recent fiscal year.

What is MIRM EV/EBITDA?

Mirum Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -7.25. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

MIRM Overview MIRM Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.